| Abstract: | Researchers have been looking for another therapy that would stimulate the body's immune system. One drug showing possibility is Interleukin-2 (IL-2), a naturally occurring chemical that already has approval by the Food and Drug Administration (FDA) for kidney cancer. IL-2 has been studied in conjunction with HIV infection since 1981. Clinical trials with the drug have demonstrated dramatic and sustained CD4 increases that apparently surpass those in other forms of therapy, including protease inhibitors. One major drawback to IL-2 treatment is its administration, which is either injection under the skin or infusion directly into a vein or muscle. Flu-like symptoms are a common side effect and may be lessened by antihistamines and ibuprofen given before treatment. Contact information for two clinical trials is provided. |
